BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 17384658)

  • 1. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients.
    Heining C; Spyridonidis A; Bernhardt E; Schulte-Mönting J; Behringer D; Grüllich C; Jakob A; Bertz H; Finke J
    Bone Marrow Transplant; 2007 May; 39(10):613-22. PubMed ID: 17384658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative lymphocyte subset reconstitution after allogeneic hematopoietic transplantation from matched related donors with CD34+ selected PBPC grafts unselected PBPC grafts or BM grafts.
    Behringer D; Bertz H; Schmoor C; Berger C; Dwenger A; Finke J
    Bone Marrow Transplant; 1999 Aug; 24(3):295-302. PubMed ID: 10455369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose.
    Min CK; Kim DW; Lee JW; Han CW; Min WS; Kim CC
    Haematologica; 2001 Mar; 86(3):303-10. PubMed ID: 11255278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune reconstitution after purified autologous and allogeneic blood stem cell transplantation compared with unmanipulated bone marrow transplantation in children.
    Schwinger W; Weber-Mzell D; Zois B; Rojacher T; Benesch M; Lackner H; Dornbusch HJ; Sovinz P; Moser A; Lanzer G; Schauenstein K; Ofner P; Handgretinger R; Urban C
    Br J Haematol; 2006 Oct; 135(1):76-84. PubMed ID: 16925797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
    Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
    Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT.
    Scholl S; Mügge LO; Issa MC; Kasper C; Pachmann K; Höffken K; Sayer HG
    Bone Marrow Transplant; 2005 Jan; 35(2):183-90. PubMed ID: 15531897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different immune reconstitution in multiple myeloma, chronic myeloid leukemia and acute myeloid leukemia patients after allogeneic transplantation of peripheral blood stem cells.
    Rondelli D; Re F; Bandini G; Raspadori D; Arpinati M; Senese B; Stanzani M; Bonifazi F; Falcioni S; Chirumbolo G; Tura S
    Bone Marrow Transplant; 2000 Dec; 26(12):1325-31. PubMed ID: 11223973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies.
    Chen X; Hale GA; Barfield R; Benaim E; Leung WH; Knowles J; Horwitz EM; Woodard P; Kasow K; Yusuf U; Behm FG; Hayden RT; Shurtleff SA; Turner V; Srivastava DK; Handgretinger R
    Br J Haematol; 2006 Nov; 135(4):524-32. PubMed ID: 17010105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reconstitution of the Ig heavy chain CDR3 repertoire after allogeneic haematopoietic stem cell transplantation with myeloablative or reduced-intensity conditioning regimens.
    Omazic B; Hentschke P; Näsman-Björk I; Mattsson J; Oxelius VA; Ringdén O; Barkholt L; Permert J; Lundkvist I
    Scand J Immunol; 2005 Jan; 61(1):72-81. PubMed ID: 15644125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
    Yang K; Fan ZP; Liu QF; Zhang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
    Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
    Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4(+) lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients.
    Jaskula E; Dlubek D; Duda D; Bogunia-Kubik K; Mlynarczewska A; Lange A
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1296-305. PubMed ID: 19747638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
    Huang XJ; Xu LP; Ren HY; Zhang YC; Guo NL; Lu DP
    Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):766-9. PubMed ID: 12899755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-intensity conditioning regimen preserves thymic function in the early period after hematopoietic stem cell transplantation.
    Jiménez M; Martínez C; Ercilla G; Carreras E; Urbano-Ispízua A; Aymerich M; Villamor N; Amézaga N; Rovira M; Fernández-Avilés F; Gaya A; Martino R; Sierra J; Montserrat E
    Exp Hematol; 2005 Oct; 33(10):1240-8. PubMed ID: 16219547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Rupa-Matysek J; Lewandowski K; Nowak W; Sawiński K; Gil L; Komarnicki M
    Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation.
    Saito T; Kanda Y; Nakai K; Kim SW; Arima F; Kami M; Tanosaki R; Tobinai K; Wakasugi H; Heike Y; Mineishi S; Takaue Y
    Bone Marrow Transplant; 2003 Sep; 32(6):601-8. PubMed ID: 12953133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.